Affiliation:
1. AniCura Vetsia Veterinary Hospital Leganés Madrid Spain
2. Hospital Clínico Veterinario Complutense Universidad Complutense de Madrid Madrid Spain
Abstract
AbstractA 2‐year‐old, neutered, female beagle was presented to a referral hospital for investigation of pancytopenia. The patient had a history of recurrent infections and, on previous blood tests, anaemia, leukopenia and thrombocytopenia were detected. At the time of presentation, the patient had been treated for 2 weeks with omeprazole, amoxicillin‐clavulanic acid, marbofloxacin and gabapentin, and for 3 months with prednisolone, in decreasing doses. A bone marrow aspirate and core biopsy were performed. Hypoplastic bone marrow was observed. Once underlying infectious diseases and exposure to toxins were ruled out, a diagnosis of aplastic anaemia was made. The patient was treated with eltrombopag, a thrombopoietin receptor agonist that stimulates primitive haematopoietic stem cells, used for the treatment of aplastic anaemia in humans. One week after starting eltrombopag treatment, all the affected cellular lines were recovered. The patient continued in remission 7 months after treatment.
Reference34 articles.
1. Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia
2. FTrisankizumab.Anexo I: Ficha técnica o resumen de las características del producto 1.Agencia Eur Medicam;2022. p.1–33.https://www.ema.europa.eu/en/documents/product‐information/skyrizi‐epar‐product‐information_es.pdfAccesed on January 2nd 2023
3. Activity of eltrombopag in severe aplastic anemia
4. Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia
5. Current evidence and the emerging role of eltrombopag in severe aplastic anemia